Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial
- Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment
- Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care
- Enhances clinical profile of aXess, reinforcing excellent first-in-human outcomes amid ongoing US pivotal trial and ahead of commercialization
EINDHOVEN, The Netherlands, 24 September 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces successful clinical data from the aXess EU pivotal trial, demonstrating the transformative potential of aXess in hemodialysis treatment.
